comparemela.com

Latest Breaking News On - Networking lounge - Page 6 : comparemela.com

Global industry experts to speak at F2F Sourcing Show 2021

Global industry experts to speak at F2F Sourcing Show 2021
fibre2fashion.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fibre2fashion.com Daily Mail and Mail on Sunday newspapers.

Insights on Retail 2022, Inflation & Industry 4 0 at F2F Sourcing Show

The upcoming edition of F2F Sourcing Show will see several industry experts share their knowledge on pertinent subjects. The 2nd edition of the virtual trade show for the.

Major fashion brands to source at Fibre2Fashion Trade Show

Major fashion brands to source at Fibre2Fashion Trade Show ANI | Updated: Jul 23, 2021 10:13 IST Ahmedabad (Gujarat) [India], July 23 (ANI/BusinessWire India): The forthcoming second edition of F2F Sourcing Show promises to provide access to unlimited business and networking opportunities for global visitors for sourcing their textile-apparel-fashion needs. The two-week virtual trade event for apparel, fabric, and yarn exhibitors, being organised by Fibre2Fashion, is scheduled to be held from September 6, 2021. Among the several leading companies that will be attending the F2F Sourcing Show 2021 as buyers are Spain s Zara, part of the world s biggest fashion group Inditex, French fashion retail company Kiabi, Irish clothing manufacturer Portwest, and Denmark-based apparel retailer Sportmaster.

DBV Technologies S A : DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the virtual American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Scientific meeting, February 26 - March 1, 2021. Two scientific presentations have been accepted, including one clinical and one non-clinical poster. DBV will also host a virtual booth in the AAAAI virtual exhibit hall. The data to be presented will discuss a post-hoc analysis of the 12-month Phase 3 PEPITES clinical trial, showing that daily epicutaneous immunotherapy (EPIT) with DBV712 250 µg may reduce the severity of allergic reactions in peanut-allergic children aged 4 to 11 years. Additionally, DBV will present pre-clinical data suggesting that EPIT reduced mast-cell degranulation v

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.